Natus Medical Beats on Both Top and Bottom Lines

Seth Jayson, The Motley Fool
Updated

Natus Medical (NAS: BABY) reported earnings on May 20. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q1), Natus Medical beat slightly on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded significantly. Non-GAAP earnings per share grew significantly. GAAP earnings per share increased significantly.


Margins expanded across the board.

Revenue details
 Natus Medical booked revenue of $85.8 million. The two analysts polled by S&P Capital IQ expected sales of $84.7 million on the same basis. GAAP reported sales were 44% higher than the prior-year quarter's $59.5 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.15. The four earnings estimates compiled by S&P Capital IQ averaged $0.11 per share. Non-GAAP EPS of $0.15 for Q1 were 114% higher than the prior-year quarter's $0.07 per share. GAAP EPS of $0.11 for Q1 were much higher than the prior-year quarter's $0.01 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 57.4%, 120 basis points better than the prior-year quarter. Operating margin was 5.7%, 420 basis points better than the prior-year quarter. Net margin was 4.0%, 340 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $88.9 million. On the bottom line, the average EPS estimate is $0.19.

Next year's average estimate for revenue is $364.4 million. The average EPS estimate is $0.83.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,228 members out of 1,257 rating the stock outperform, and 29 members rating it underperform. Among 331 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 321 give Natus Medical a green thumbs-up, and 10 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Natus Medical is hold, with an average price target of $16.00.

Is Natus Medical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.

The article Natus Medical Beats on Both Top and Bottom Lines originally appeared on Fool.com.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool recommends Natus Medical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement